Literature DB >> 33622049

Regenerative medicine clinical readiness.

Satsuki Yamada1,2, Atta Behfar1,3, Andre Terzic1,4.   

Abstract

Regenerative medicine, poised to transform 21st century healthcare, has aspired to enrich care options by bringing cures to patients in need. Science-driven responsible and regulated translation of innovative technology has enabled the launch of previously unimaginable care pathways adopted prudently for select serious diseases and disabilities. The collective resolve to advance the design, manufacture and validity of affordable regenerative solutions aims to democratize such health benefits for all. The objective of this Review is to outline the framework and prerequisites that underpin clinical readiness of regenerative care. Integrated research and development, specialized workforce education and accessible evidence-based practice implementation are at the core of realizing an equitable regenerative medicine vision.

Entities:  

Keywords:  chronic disease; healthcare delivery; innovation; manufacturing; model of care; patient; population; practice; regeneration; regulation; supply chain; workforce

Mesh:

Year:  2021        PMID: 33622049      PMCID: PMC8050983          DOI: 10.2217/rme-2020-0178

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  111 in total

1.  Chronic diseases: the emerging pandemic.

Authors:  Andre Terzic; Scott Waldman
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

2.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

Authors:  Enli Liu; David Marin; Pinaki Banerjee; Homer A Macapinlac; Philip Thompson; Rafet Basar; Lucila Nassif Kerbauy; Bethany Overman; Peter Thall; Mecit Kaplan; Vandana Nandivada; Indresh Kaur; Ana Nunez Cortes; Kai Cao; May Daher; Chitra Hosing; Evan N Cohen; Partow Kebriaei; Rohtesh Mehta; Sattva Neelapu; Yago Nieto; Michael Wang; William Wierda; Michael Keating; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  N Engl J Med       Date:  2020-02-06       Impact factor: 91.245

3.  Regenerative outlook: offering global solutions for equitable care.

Authors:  Freya Leask; Andre Terzic
Journal:  Regen Med       Date:  2020-11-27       Impact factor: 3.806

Review 4.  Clinical Experience With Regenerative Therapy in Heart Failure: Advancing Care With Cardiopoietic Stem Cell Interventions.

Authors:  Jozef Bartunek; Andre Terzic; Atta Behfar; William Wijns
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

5.  Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing.

Authors:  Fadi Jacob; Guo-Li Ming; Hongjun Song
Journal:  Nat Protoc       Date:  2020-11-09       Impact factor: 13.491

6.  Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals.

Authors:  Magdi Elsallab; Christopher A Bravery; Andreas Kurtz; Mohamed Abou-El-Enein
Journal:  Mol Ther Methods Clin Dev       Date:  2020-06-03       Impact factor: 6.698

7.  Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.

Authors:  Elisabete Gonçalves
Journal:  Eur J Health Econ       Date:  2020-01-09

Review 8.  Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies.

Authors:  Roya Ramezankhani; Shukoofeh Torabi; Neda Minaei; Hoda Madani; Siamak Rezaeiani; Seyedeh Nafiseh Hassani; Adrian P Gee; Massimo Dominici; Daniela Nascimento Silva; Hossein Baharvand; Ensiyeh Hajizadeh-Saffar
Journal:  Front Cell Dev Biol       Date:  2020-12-17

Review 9.  Engineering precision nanoparticles for drug delivery.

Authors:  Michael J Mitchell; Margaret M Billingsley; Rebecca M Haley; Marissa E Wechsler; Nicholas A Peppas; Robert Langer
Journal:  Nat Rev Drug Discov       Date:  2020-12-04       Impact factor: 84.694

Review 10.  Stem cell preservation for regenerative therapies: ethical and governance considerations for the health care sector.

Authors:  Zubin Master; Aidan P Crowley; Cambray Smith; Dennis Wigle; Andre Terzic; Richard R Sharp
Journal:  NPJ Regen Med       Date:  2020-12-01
View more
  3 in total

1.  Evidence generation and reproducibility in cell and gene therapy research: A call to action.

Authors:  Mohamed Abou-El-Enein; Aris Angelis; Frederick R Appelbaum; Nancy C Andrews; Susan E Bates; Arlene S Bierman; Malcolm K Brenner; Marina Cavazzana; Michael A Caligiuri; Hans Clevers; Emer Cooke; George Q Daley; Victor J Dzau; Lee M Ellis; Harvey V Fineberg; Lawrence S B Goldstein; Stephen Gottschalk; Margaret A Hamburg; Donald E Ingber; Donald B Kohn; Adrian R Krainer; Marcela V Maus; Peter Marks; Christine L Mummery; Roderic I Pettigrew; Joni L Rutter; Sarah A Teichmann; Andre Terzic; Fyodor D Urnov; David A Williams; Jedd D Wolchok; Mark Lawler; Cameron J Turtle; Gerhard Bauer; John P A Ioannidis
Journal:  Mol Ther Methods Clin Dev       Date:  2021-07-21       Impact factor: 6.698

Review 2.  Mass Customized Outlook for Regenerative Heart Failure Care.

Authors:  Satsuki Yamada; Jozef Bartunek; Atta Behfar; Andre Terzic
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

3.  Screening for regenerative therapy responders in heart failure.

Authors:  Satsuki Yamada; Ryounghoon Jeon; Armin Garmany; Atta Behfar; Andre Terzic
Journal:  Biomark Med       Date:  2021-06-25       Impact factor: 2.851

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.